Oncology (all articles)
RCT: Apatinib improves outcomes compared to placebo in patients with locally advanced or metastatic, radioactive iodine–refractory differentiated thyroid cancer.
10 Feb, 2022 | 09:56h | UTC
Commentary on Twitter
Apatinib offered significant clinical benefits in terms of both prolonged progression-free survival and overall survival in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. https://t.co/I14AyxKZNS
— JAMA Oncology (@JAMAOnc) December 16, 2021
Australasian Consensus Guidelines for the use of antifungal agents in the hematology-oncology setting.
9 Feb, 2022 | 08:49h | UTCConsensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Expert Consensus: Treatment algorithm in cancer-associated thrombosis.
9 Feb, 2022 | 08:42h | UTC
M-A: Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma.
9 Feb, 2022 | 08:39h | UTC
M-A: Neoadjuvant therapy vs. direct to surgery for T4 colon cancer.
9 Feb, 2022 | 08:28h | UTCNeoadjuvant therapy versus direct to surgery for T4 colon cancer: meta-analysis – British Journal of Surgery (link to abstract – $ for full-text)
Expert panel consensus on management of advanced cancer–related pain in individuals with opioid use disorder.
8 Feb, 2022 | 08:49h | UTCCommentaries:
Guidance Offered for Managing Pain in Patients With Cancer and OUD – HealthDay
Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer.
8 Feb, 2022 | 08:31h | UTCExpert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer – ESMO Open
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
7 Feb, 2022 | 08:36h | UTC
NCCN Guidelines Insights: Squamous Cell Skin Cancer, Version 1.2022.
7 Feb, 2022 | 08:34h | UTC
RCT: Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema.
4 Feb, 2022 | 08:35h | UTC
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.
4 Feb, 2022 | 08:38h | UTCOriginal Study: Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
RCT: In patients with advanced esophageal squamous-cell carcinoma, both nivolumab plus chemotherapy and nivolumab plus ipilimumab resulted in longer overall survival than chemotherapy alone.
3 Feb, 2022 | 09:46h | UTCNivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary (2021 ASCO Annual Meeting): Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer – The ASCO Post
Commentary on Twitter
First-line treatment of advanced esophageal squamous-cell carcinoma with either nivolumab plus chemo or nivolumab plus ipilimumab resulted in a significant overall survival benefit and durable responses as compared with chemo alone. https://t.co/a000bDsh1N pic.twitter.com/NuY2eX58gp
— NEJM (@NEJM) February 2, 2022
Guideline: atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).
3 Feb, 2022 | 08:48h | UTC
M-A: Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials.
3 Feb, 2022 | 08:31h | UTC
Commentary on Twitter
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysishttps://t.co/cnLe3oxATE@ricautor @spsutkaMD @MRoupret @AndreaNecchi @pcvblack pic.twitter.com/EmeapD8O54
— European Urology (@EUplatinum) January 30, 2022
Increasing financial payments from industry to medical oncologists in the U.S., 2014-2017.
3 Feb, 2022 | 08:26h | UTCInvited Commentary: Physician Interactions With Industry: Striking the Right Balance – Journal of the National Comprehensive Cancer Network
M-A: Laparoscopic versus open distal gastrectomy for gastric cancer.
3 Feb, 2022 | 08:30h | UTC
NCCN Guideline: Kidney Cancer.
2 Feb, 2022 | 08:30h | UTC
Review: Primary and metastatic peritoneal surface malignancies.
2 Feb, 2022 | 08:33h | UTCPrimary and metastatic peritoneal surface malignancies – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Primary and metastatic peritoneal surface malignancies – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Commentary on Twitter
Treatment modalities for #peritoneal surface malignancies can be combined or used sequentially according to underlying #tumour type, disease extent and patients' condition and preference.https://t.co/cIkVAJRSaj pic.twitter.com/PUP1BtoTxE
— Nature Reviews Disease Primers (@DiseasePrimers) December 21, 2021
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicenter pooled analysis of 5161 patients.
2 Feb, 2022 | 08:22h | UTC
Review: Diagnosis and Management of Multiple Myeloma.
2 Feb, 2022 | 08:11h | UTCDiagnosis and Management of Multiple Myeloma: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Multiple Myeloma – JAMA
Observational Study: Same-day mastectomy and axillary lymph node dissection seems safe for most patients with breast cancer.
1 Feb, 2022 | 08:38h | UTC
RCT: Sugemalimab improves progression-free survival vs. placebo in patients with metastatic non-small-cell lung cancer.
1 Feb, 2022 | 08:25h | UTCSugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial – The Lancet Oncology (link to abstract – $ for full-text)
Related study: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Sugemalimab shows promise for locally advanced, metastatic NSCLC – Medicine Matters
Sugemalimab Boosts Outcomes in NSCLC – MedPage Today (free registration required)
Commentary on Twitter
https://twitter.com/NatRevClinOncol/status/1483839169839255554
Meta-analysis: Androgen deprivation therapy, in addition to radiotherapy, is associated with improved metastasis-free survival in men with localized prostate cancer.
1 Feb, 2022 | 08:24h | UTCAndrogen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)
RCT: Olanzapine may improve the control of vomiting in the delayed phase in children receiving highly emetogenic chemotherapy.
30 Jan, 2022 | 14:13h | UTCEfficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial – Journal of Pediatric Hematology/Oncology (link to abstract – $ for full-text)
Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
30 Jan, 2022 | 14:11h | UTCOriginal Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
Related:
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)